204 related articles for article (PubMed ID: 28267814)
1. Safety after extended repeated use of ulipristal acetate for uterine fibroids.
Fauser BC; Donnez J; Bouchard P; Barlow DH; Vázquez F; Arriagada P; Skouby SO; Palacios S; Tomaszewski J; Lemieszczuk B; William AR
PLoS One; 2017; 12(3):e0173523. PubMed ID: 28267814
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment of uterine fibroids with ulipristal acetate ☆.
Donnez J; Vázquez F; Tomaszewski J; Nouri K; Bouchard P; Fauser BC; Barlow DH; Palacios S; Donnez O; Bestel E; Osterloh I; Loumaye E;
Fertil Steril; 2014 Jun; 101(6):1565-73.e1-18. PubMed ID: 24630081
[TBL] [Abstract][Full Text] [Related]
3. Long-term medical management of uterine fibroids with ulipristal acetate.
Donnez J; Donnez O; Matule D; Ahrendt HJ; Hudecek R; Zatik J; Kasilovskiene Z; Dumitrascu MC; Fernandez H; Barlow DH; Bouchard P; Fauser BC; Bestel E; Loumaye E
Fertil Steril; 2016 Jan; 105(1):165-173.e4. PubMed ID: 26477496
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids.
Donnez J; Hudecek R; Donnez O; Matule D; Arhendt HJ; Zatik J; Kasilovskiene Z; Dumitrascu MC; Fernandez H; Barlow DH; Bouchard P; Fauser BC; Bestel E; Terrill P; Osterloh I; Loumaye E
Fertil Steril; 2015 Feb; 103(2):519-27.e3. PubMed ID: 25542821
[TBL] [Abstract][Full Text] [Related]
5. Endometrial changes during ulipristal acetate use: A systematic review.
De Milliano I; Van Hattum D; Ket JCF; Huirne JAF; Hehenkamp WJK
Eur J Obstet Gynecol Reprod Biol; 2017 Jul; 214():56-64. PubMed ID: 28482329
[TBL] [Abstract][Full Text] [Related]
6. Hysteroscopic Patterns in Women on Treatment With Ulipristal Acetate 5 mg/day: A Preliminary Study.
Bettocchi S; Baranowski WE; Doniec J; Ceci O; Resta L; Fascilla FD; Mitola PC; Tinelli R; Cicinelli E
J Minim Invasive Gynecol; 2016; 23(5):664-9. PubMed ID: 26803918
[TBL] [Abstract][Full Text] [Related]
7. Phase III long-term study to evaluate the efficacy and safety of ulipristal acetate in Japanese patients with uterine fibroids.
Osuga Y; Nakano Y; Yamauchi Y; Murakawa H
J Obstet Gynaecol Res; 2021 Sep; 47(9):3269-3278. PubMed ID: 34109697
[TBL] [Abstract][Full Text] [Related]
8. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
[TBL] [Abstract][Full Text] [Related]
9. A prospective, open-label, multicenter study to assess the pharmacodynamics and safety of repeated use of 30 mg ulipristal acetate.
Jesam C; Cochon L; Salvatierra AM; Williams A; Kapp N; Levy-Gompel D; Brache V
Contraception; 2016 Apr; 93(4):310-316. PubMed ID: 26764121
[TBL] [Abstract][Full Text] [Related]
10. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
Szamatowicz M; Kotarski J
Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
[TBL] [Abstract][Full Text] [Related]
11. The endometrial response to modulation of ligand-progesterone receptor pathways is reversible.
Chodankar RR; Murray A; Nicol M; Whitaker LHR; Williams ARW; Critchley HOD
Fertil Steril; 2021 Sep; 116(3):882-895. PubMed ID: 33865567
[TBL] [Abstract][Full Text] [Related]
12. Endometrial Effects of Prolonged Therapy with the Selective Progesterone Receptor Modulator Ulipristal Acetate: A Case Report.
Levy G; Elkas J; Armstrong AY; Nieman LK
J Reprod Med; 2016; 61(3-4):159-62. PubMed ID: 27172639
[TBL] [Abstract][Full Text] [Related]
13. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
Williams AR; Bergeron C; Barlow DH; Ferenczy A
Int J Gynecol Pathol; 2012 Nov; 31(6):556-69. PubMed ID: 23018219
[TBL] [Abstract][Full Text] [Related]
14. Application of ulipristal acetate in female patients with uterine fibroids.
Grzechocinska B; Gadomska H; Zygula A; Wielgos M
Neuro Endocrinol Lett; 2014; 35(3):175-8. PubMed ID: 24977963
[TBL] [Abstract][Full Text] [Related]
15. Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues.
Pérez-López FR
Climacteric; 2015 Apr; 18(2):177-81. PubMed ID: 25390187
[TBL] [Abstract][Full Text] [Related]
16. Sonographic and hysteroscopic endometrial examination in women treated with ulipristal acetate: Exploratory findings at a tertiary referral center.
Gracia M; Nonell R; Ros C; Rius M; Quintas L; Martínez-Zamora MÁ; Carmona F
Eur J Obstet Gynecol Reprod Biol; 2019 Jan; 232():40-45. PubMed ID: 30468982
[TBL] [Abstract][Full Text] [Related]
17. Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids.
Tafi E; Scala C; Leone Roberti Maggiore U; Bizzarri N; Candiani M; Venturini PL; Ferrero S
Expert Opin Drug Saf; 2015 Jun; 14(6):965-77. PubMed ID: 25772793
[TBL] [Abstract][Full Text] [Related]
18. Ulipristal acetate in symptomatic uterine fibroids. A real-world experience in a multicentric Italian study.
Giarrè G; Franchini M; Castellacci E; Malune ME; Di Spiezio Sardo A; Saccone G; Angioni S
Gynecol Endocrinol; 2020 Feb; 36(2):171-174. PubMed ID: 31392917
[TBL] [Abstract][Full Text] [Related]
19. Selective progesterone receptor modulator (SPRM) ulipristal acetate (UPA) and its effects on the human endometrium.
Whitaker LH; Murray AA; Matthews R; Shaw G; Williams AR; Saunders PT; Critchley HO
Hum Reprod; 2017 Mar; 32(3):531-543. PubMed ID: 28130434
[TBL] [Abstract][Full Text] [Related]
20. Ulipristal acetate versus placebo for fibroid treatment before surgery.
Donnez J; Tatarchuk TF; Bouchard P; Puscasiu L; Zakharenko NF; Ivanova T; Ugocsai G; Mara M; Jilla MP; Bestel E; Terrill P; Osterloh I; Loumaye E;
N Engl J Med; 2012 Feb; 366(5):409-20. PubMed ID: 22296075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
